» Articles » PMID: 28298647

Inhibition of the Mechano-enzymatic Amyloidogenesis of Transthyretin: Role of Ligand Affinity, Binding Cooperativity and Occupancy of the Inner Channel

Overview
Journal Sci Rep
Specialty Science
Date 2017 Mar 17
PMID 28298647
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Dissociation of the native transthyretin (TTR) tetramer is widely accepted as the critical step in TTR amyloid fibrillogenesis. It is modelled by exposure of the protein to non-physiological low pH in vitro and is inhibited by small molecule compounds, such as the drug tafamidis. We have recently identified a new mechano-enzymatic pathway of TTR fibrillogenesis in vitro, catalysed by selective proteolytic cleavage, which produces a high yield of genuine amyloid fibrils. This pathway is efficiently inhibited only by ligands that occupy both binding sites in TTR. Tolcapone, which is bound with similar high affinity in both TTR binding sites without the usual negative cooperativity, is therefore of interest. Here we show that TTR fibrillogenesis by the mechano-enzymatic pathway is indeed more potently inhibited by tolcapone than by tafamidis but neither, even in large molar excess, completely prevents amyloid fibril formation. In contrast, mds84, the prototype of our previously reported bivalent ligand TTR 'superstabiliser' family, is notably more potent than the monovalent ligands and we show here that this apparently reflects the critical additional interactions of its linker within the TTR central channel. Our findings have major implications for therapeutic approaches in TTR amyloidosis.

Citing Articles

Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence.

Ogieuhi I, Ugiomoh O, Muzofa K, Callender K, Ayodeji J, Nnekachi N Egypt Heart J. 2024; 76(1):90.

PMID: 38985360 PMC: 11236832. DOI: 10.1186/s43044-024-00517-y.


3-O-Methyltolcapone and Its Lipophilic Analogues Are Potent Inhibitors of Transthyretin Amyloidogenesis with High Permeability and Low Toxicity.

Poonsiri T, DellAccantera D, Loconte V, Casnati A, Cervoni L, Arcovito A Int J Mol Sci. 2024; 25(1).

PMID: 38203650 PMC: 10779086. DOI: 10.3390/ijms25010479.


A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.

Patil M, Ghode P, Joshi P Mini Rev Med Chem. 2023; 24(6):571-587.

PMID: 37828667 DOI: 10.2174/0113895575241556231003055323.


Transient On- and Off-Pathway Protein Folding Intermediate States Characterized with NMR Relaxation Dispersion.

Meinhold D, Felitsky D, Dyson H, Wright P J Phys Chem B. 2022; 126(46):9539-9548.

PMID: 36354189 PMC: 9793904. DOI: 10.1021/acs.jpcb.2c05592.


Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation.

Pinheiro F, Pallares I, Peccati F, Sanchez-Morales A, Varejao N, Bezerra F J Med Chem. 2022; 65(21):14673-14691.

PMID: 36306808 PMC: 9661476. DOI: 10.1021/acs.jmedchem.2c01195.


References
1.
Hosoi A, Su Y, Torikai M, Jono H, Ishikawa D, Soejima K . Novel Antibody for the Treatment of Transthyretin Amyloidosis. J Biol Chem. 2016; 291(48):25096-25105. PMC: 5122777. DOI: 10.1074/jbc.M116.738138. View

2.
Palaninathan S . Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?. Curr Med Chem. 2012; 19(15):2324-42. DOI: 10.2174/092986712800269335. View

3.
Gilson M, Zhou H . Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct. 2007; 36:21-42. DOI: 10.1146/annurev.biophys.36.040306.132550. View

4.
SantAnna R, Gallego P, Robinson L, Pereira-Henriques A, Ferreira N, Pinheiro F . Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016; 7:10787. PMC: 4766415. DOI: 10.1038/ncomms10787. View

5.
Johnson S, Petrassi H, Palaninathan S, Mohamedmohaideen N, Purkey H, Nichols C . Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem. 2005; 48(5):1576-87. DOI: 10.1021/jm049274d. View